Type 1 corticotropin-releasing factor receptors in the ventromedial hypothalamus promote hypoglycemia-induced hormonal counterregulation

Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut Submitted 28 February 2007 ; accepted in final form 8 June 2007 Type 2 corticotropin-releasing factor (CRF) receptors (CRFR2) within the ventromedial hypothalamus (VMH), a key glucose-sensing region, play a m...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of physiology: endocrinology and metabolism Vol. 293; no. 3; pp. E705 - E712
Main Authors Cheng, Haiying, Zhou, Ligang, Zhu, Wanling, Wang, Ajin, Tang, Chuyan, Chan, Owen, Sherwin, Robert S, McCrimmon, Rory J
Format Journal Article
LanguageEnglish
Published United States American Physiological Society 01.09.2007
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut Submitted 28 February 2007 ; accepted in final form 8 June 2007 Type 2 corticotropin-releasing factor (CRF) receptors (CRFR2) within the ventromedial hypothalamus (VMH), a key glucose-sensing region, play a major role in regulating the hormonal counterregulatory responses (CRRs) to acute hypoglycemia. The VMH expresses both subtypes of CRF receptors, CRFR1 and CRFR2. The objective of this study was to examine the role of the CRFR1 receptor in the VMH in the regulation of the CRR to acute hypoglycemia. To compare the hormonal CRR to hypoglycemia, awake and unrestrained Sprague-Dawley rats were bilaterally microinjected to the VMH with either 1 ) aECF, 2 ) CRF (1 pmol/side), 3 ) CRFR1 antagonist Antalarmin (500 pmol/side), or 4 ) CRF + Antalarmin prior to undergoing a hyperinsulinemic hypoglycemic (2.8 mM) clamp. A second series of studies also incorporated an infusion of [ 3 H]glucose to allow the calculation of glucose dynamics. In addition the effect of CRFR1 antagonism in the paraventricular nucleus (PVN) was studied. Activation of VMH CRFR1 increased, whereas inhibition of CRFR1 suppressed hypoglycemia-induced CRRs. Inhibition of VMH CRFR1 also increased peripheral glucose utilization and reduced endogenous glucose production during hypoglycemia, whereas VMH CRF reduced peripheral glucose utilization. In contrast CRFR1 inhibition in the PVN blunted corticosterone but not epinephrine or glucagon CRR to hypoglycemia. In contrast to CRFR2 activation, CRFR1 activation within the VMH amplifies CRRs to acute hypoglycemia. The balance between these two opposing CRFRs in this key glucose-sensing region may play an important role in determining the magnitude of CRRs to acute hypoglycemia. type 1 diabetes; epinephrine; glucagon Address for reprint requests and other correspondence: R. J. McCrimmon, Dept. of Internal Medicine-Section of Endocrinology, Yale Univ. School of Medicine, PO Box 208020, New Haven, CT 06520 (e-mail: rory.mccrimmon{at}yale.edu )
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0193-1849
1522-1555
DOI:10.1152/ajpendo.00136.2007